New Treatment Effective In Up To 73% Of Multiple Myeloma Patients!
Heavyweight! First ADC Drug For Refractory Ovarian Cancer Receives Accelerated FDA Approval
Facing critical hypertension, how do we do well in self-care
Cancer Institute Hospital of JFCR
Car-T Therapy Ide-Cel For Multiple Myeloma Prolongs Patient Survival By 2-Fold!
Newly Approved Targeted Drug Makes 79% Of Patients' Tumours Disappear Altogether, This Type Of Blood Tumour Is Saved!
